Abstract 144P
Background
Paclitaxel is commonly used as second-line therapy in advanced gastric cancer (AGC). The decision to proceed with second-line chemotherapy and select a chemotherapy regimen may be critical in vulnerable AGC patients after progression with first-line chemotherapy. However, there are no predictive biomarkers to identify patients with AGC who benefit from paclitaxel-based chemotherapy.
Methods
This study included 288 patients with AGC receiving second-line paclitaxel-based chemotherapy between 2017 and 2022 from K-MASTER project, a nationwide, government-funded precision medicine initiative. The data included clinicogenomic factors: clinical (age [young-onset vs. others], sex, histology [intestinal vs. diffuse type], prior trastuzumab use, duration of first-line chemotherapy, etc.) and genomic factors (pathogenic or likely pathogenic variants). The data were randomly divided into training and test sets (0.8:0.2). Three machine-learning methods, including random forest (RF), logistic regression (LR), and artificial neural network with genetic embedding (ANN) models, were used to develop the prediction model and were validated in the test sets.
Results
The median age was 64 years (range, 25-91) and 65.6% were male. A total of 288 patients were divided into training (n=230) and test sets (n=58). There were no significant differences in baseline characteristics between training and test sets. In the training set, the AUC for prediction of progression-free survival (PFS) with paclitaxel-based chemotherapy was 0.51, 0.73, and 0.75 in RF, LR, and ANN models, respectively. In the test set, the Kaplan-Meier curves of PFS were separated according to the three models: 2.8 vs. 1.5 months (P=0.07) in RF, 2.3 vs. 6.5 months (P=0.07) in LR, and 2.1 vs. 7.6 months (P=0.02) in ANN models.
Conclusions
These machine-learning models integrated clinical and genomic factors and can guide the selection of patients with AGC with a greater likelihood of a benefit from second-line paclitaxel-based chemotherapy. Further studies are necessary to validate and update these models in independent datasets in future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract